RecruitingNCT04512833

CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis

CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma


Sponsor

Beijing 302 Hospital

Enrollment

60 participants

Start Date

Aug 12, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.


Eligibility

Min Age: 30 YearsMax Age: 80 Years

Inclusion Criteria10

  • Primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
  • Unfeasible or refusing to undergo other treatments;
  • Residual normal liver volume ≥700 cc;
  • With decompensated cirrhosis (Child-Pugh B or C classification);
  • Without portal vein tumor thrombus;
  • Eastern Cooperative Oncology Group (ECOG) score 0-1;
  • Distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm;
  • Rejecting other therapies such as resection, liver transplantation, etc.
  • Platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;
  • Patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.

Exclusion Criteria3

  • With Tumor thrombus;
  • With extrahepatic metastasis;
  • With lymph node involvement.

Interventions

RADIATIONCyberknife stereotactic body radiation therapy

A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis.


Locations(1)

Beijing 302 hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04512833


Related Trials